Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23303403 | 0.92 | ALDH1A1 (0.46) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10441949 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10442030 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10442037 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10442274 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10442040 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL10442132 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL8756524 | 0.90 | TSHR (0.50) | ALDH1A1TP53TSHROXER1FAAH | |
| SCHEMBL330245 | 0.83 | — | — | |
| SCHEMBL24233748 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4700017-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics Inc. (CA) | 2026-02-25 | — | — | EP | disclosed |
| EP-4448486-B1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | ACUITAS THERAPEUTICS INC (CA) | 2025-10-15 | — | — | EP | disclosed |
| US-20250092002-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | ACUITAS THERAPEUTICS INC (CA) | 2025-03-20 | — | — | US | disclosed |
| EP-4448486-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2024-01-04 | — | — | US | disclosed |
| WO-2023114944-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114944-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| US-20230183169-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | Sichuan Academy Of Medical Sciences · Sichuan Provincial People's Hospital (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-1726187-A | Substituted tetralins and indanes and their use | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-25 | — | — | CN | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556344-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183169-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | NOTUM, BYSL, TYR | ALDH1A1 1017/4885TP53 4728/4885TSHR 3789/4885 |
| US-20250092002-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | PHOSPHO1, LPAR3, RFTN1 | ALDH1A1 3754/4885TP53 1646/4885TSHR 225/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | ALDH1A1 2145/4885TP53 1033/4885TSHR 253/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3472/4885TP53 3299/4885TSHR 3959/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | ALDH1A1 2145/4885TP53 1033/4885TSHR 253/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | ALDH1A1 1536/4885TP53 502/4885TSHR 150/4885 |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3472/4885TP53 3299/4885TSHR 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.